FindTrial
Sign In

Study to evaluate accuracy of Early detection method for various cancer types for both the genders

Pilot Study for Validation of metabolite signatures across stages and types of Cancer (Stage I to Stage IV) in Adult Male Population and Female Populations using Metabolite Bio-Signatures and subsequent utilization of data on an Artificial Intelligence (AI) platform to validate an early detection software. - PDMX-05

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/03/050316
Enrollment
2700
Registered
2023-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R978- Other abnormal tumor markers

Interventions

None listed

Sponsors

Dr Imliwati Longkumer
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Cancer patients within the age group of 18 to 75 yrs 2. Individuals who have been diagnosed for any of the Cancer types

Exclusion criteria

Exclusion criteria: 1. Individuals with no known cancer, high-grade dysplasia, autoimmune disease, or chronic kidney disease. 2. Cancer patients who have received any kind of Immuno / chemo / radiation / medical / etc. therapy

Design outcomes

Primary

MeasureTime frame
Validate the established screening methodology from single sample to identify/ isolate known unknown cancer types and assist in early detection, treatment.Timepoint: Screening Day 7—

Secondary

MeasureTime frame
Validation of existing AI algorithm to ensure specificity, sensitivity and precision.Timepoint: Screening Day 7—

Countries

India

Contacts

Public ContactVikrant Tripathi

North East Cancer Hospital and Research Institute

ilongkumer@yahoo.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 5, 2026